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Abstract. – Uterus transplantation was firstly 
tested with animal trials sixty-five years ago. De-
spite several successful attempts in human sub-
jects, the different procedures still lay at the exper-
imental stage, in need of further studies and inves-
tigations before they can be considered as stan-
dard clinical practices. Uterus transplant cannot 
be regarded as a life-saving procedure, but rather a 
method to restore woman ability to procreate, 
when lost, thus improving her quality of life. Uterus 
transplant is a complex surgical procedure and 
presents significant health threats. Medical staff 
should therefore always obtain informed consent 
from patients, emphasizing such risks. Before 
that, women undergoing uterine transplants 
should be thoroughly informed about the hazards 
inherent to the procedure and especially about the 
dangers of immunosuppressant drugs, adminis-
tered after the surgery which may injure the fetus, 
eventually formed in the restored organ and even 
lead to its death, thus nullifying the purpose of the 
transplant itself. Therefore, the risk-benefit ratio of 
uterus transplantation needs to be carefully as-
sessed and described. 
Key Words
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Informed consent.
Introduction
Infertility can be considered as a medico-social 
issue and a disability1. Among its social causes, 
there is the prospective mother’s advanced age, 
drug or alcohol abuse, smoking, adverse working 
conditions and finally pollution2. On the oth-
er hand, unfavorable medical conditions include 
a lack of uterus following its surgical remov-
al (hysterectomy) or Rokitansky-Kuster-Hauser 
syndrome (Müllerian agenesis), a rare congenital 
malformation that carries varying degrees of 
vaginal or uterine hypoplasia, making the uterus 
unfit for pregnancy3. Nowadays, females who 
cannot achieve a natural pregnancy, but still 
wish to have offspring bearing their genetic 
background can appeal to surrogacy4, and 
medically assisted procreation techniques 
make such option viable5,6. These practic-
es consist in “borrowing” or “renting” the 
womb of another woman, who agrees to have 
implanted into her uterus an embryo which 
was formed in vitro via gametes from a 
couple with infertility problems. Surrogacy 
unleashes multiple ethical controversies, and 
it is outlawed in many countries, including 
Italy7, because it is perceived as damaging 
the dignity of motherhood, and turns babies 
into “tradable commodities”, often resulting 
in negotiations and litigations.
In this review, the authors aimed to briefly 
outline the history and development of uterus 
transplantation, from the first tests in animal 
model sixty-five years ago to the attempts and 
some successes in human subjects, ethical 
considerations and what is required for the 
different procedures, many of them still at 
the experimental stage, before they can be 
considered as standard clinical practices. 
Historical Background of Uterus 
Transplantation: Research Trials 
on Animals and Human Subjects
The first animal trials concerning uterus 
transplantation started around 1950, whereas the 
first attempt on a human female took place about 
40 years ago, in the same Cape Town hospital 
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where Cristian Barnard performed the first heart 
transplant: the outcome was disastrous. 
In 2000, the first transplant of the new century 
took place and demonstrated that such surgery 
was technically possible. In that specific case, 
the pregnancy had to be terminated because 
of arising vascular issues8,9. Nonetheless, med-
ical staff expressed a positive judgment on the 
surgery itself, thus laying the groundwork for 
further improvement in surgical techniques. In 
2008, the ethical committee of International Fed-
eration of Gynecology and Obstetrics (FIGO) 
issued a report that classified uterus transplants 
as unethical, due to a lack of data about its safety 
and effectiveness10. Nonetheless, human clinical 
trials have continued, with many of them carried 
out in Turkey, where surgeons used organs from 
deceased donors and attained pregnancies, which 
eventually ended in miscarriages11.
In 2012, the Ethical Committee at Gothen-
burg’s University Hospital (Sweden) green-light-
ed ten uterine transplants from living donors. 
The first one was executed in September 2012, 
and a year later patient underwent immuno-
suppressive drug therapy and eventual in-vitro 
fertilization, in an attempt to achieve pregnan-
cy. Two pregnancies were ultimately carried to 
term, after which the transplanted uterus was 
removed in order to discontinue immunosup-
pressive drug therapy12,13. 
Another similar attempt was made in Cleve-
land, United States, on 24th February 2016. The 
recipient was a 26-year-old female included in a 
research trial totaling 10 transplants, whereas the 
uterus came from a 30-year-old deceased donor. 
The surgery led to an unfavorable outcome, and 
the transplanted uterus had to be removed 12 
days later, due to complications14. In the wake of 
the successful attempts in Sweden, the same year, 
specialists at the a French “Agence Nationale de 
Sécurité du Médicament authorized a series of 
trials on eight women transplanted with uterus 
from donors declared to be brain-dead. Doctors 
are set to wait for a complete stabilization of the 
transplanted organs before attempting to achieve 
pregnancy through in vitro fertilization. The first 
childbirth is scheduled to take place by the end of 
2018, according to the specialists15,16.
In Italy, the Ethical Committee of the Italian 
National Institute of Health has approved a womb 
transplant protocol at the Umberto I Hospital 
in Rome17. In the United Kingdom, the Health 
Research Authority has authorized ten uterus 
transplants18.
Generally speaking, since the year 2000, thir-
teen uterine transplants have been carried out 
in different medical institutions worldwide. A 
total of four children were born, and one wom-
an even bore a second child in October 2015. 
Although such few but successful results have 
been attained be encouraging, the FIGO has not 
yet revised its assessment on uterus transplants 
non-ethics, which was released in 2008. 
Uterus Transplant: Risk-benefit Analysis
Almost twenty years later, uterine transplant 
falls within the field of clinical as well as ther-
apeutic research, since women who undergo it 
hope for an opportunity to get pregnant, thus 
benefiting from the procedure on a personal level. 
This kind of transplant requires surgical practices 
still in the process of being improved, such as 
anastomosis (i.e., the procedure through which 
blood vessels and arteries can be connected), 
in addition to more consolidated ones. Unlike 
other organs, which have larger veins capable of 
transporting large amounts of blood, the uter-
us has very thin vessels, which are difficult to 
re-connect. 
Moreover, a uterine transplant offers only 
minimal chances to attain pregnancy. On the 
other hand, it implies substantial risks, which 
make necessary a long and thorough experimen-
tal phase starting with animal trials. The latest 
version of the Italian Code of Medical Ethics 19,20 
recommends doctors to refrain from diagnostic 
and therapeutic procedures that might be viewed 
as clinically unwarranted and ethically ques-
tionable, and from those who cannot reasonably 
provide tangible benefits to the patient’s health 
and quality of life (art. 16, Code of Medical Eth-
ics). However, the remarkable rate of progress in 
medical transplantation techniques and biomed-
ical engineering will hopefully improve uterine 
transplants as well, which anyway impact a fairly 
small amount of patients and poses multiple sci-
entific and medical issues.
Ethical Issues: The Montreal Criteria
Uterine transplantation is a complex proce-
dure that gives rise to multiple medical, ethical 
and legal inquiries due to the risks posed to both 
donors and recipients.
For all those reasons, in 2012, Lefkowitz et 
al21 have released a set of arguments both for 
and against uterus transplantation (Utx), known 
as “the Montreal criteria”, which have been up-
dated the following year22. The revised Montreal 
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criteria for the ethical feasibility of uterine trans-
plantation involve recipients, donors and medical 
staff, and have to be met as a whole, for a uterus 
transplant to be considered ethically viable.
Such criteria break down as follows:
1. The recipient 
a Genetic female of reproductive age with no 
medical contraindications to transplantation;
b Presence of documented congenital or ac-
quired uterine factor infertility (UFI) that 
failed all current gold standard and conserva-
tive therapies;
c
c1 A personal or legal contraindication to surrogacy 
and adoption measures and desire to have a child;
c2 Uterus transplantation (UTx) sought only as 
a measure to experience gestation, with an 
understanding of the limitations provided by 
the UTx in this respect;
d The decision to undergo UTxis not deemed as 
irrational by expert psychological evaluation, 
and no psychological comorbidity that interferes 
with diagnostic workup or treatment is present;
e No frank unsuitability for motherhood;
f Likely to take anti-rejection medication and 
follow-up with the treating team in a respon-
sible manner, and 
g Responsible enough to consent, informed 
enough to make a responsible decision. 
2. The donor 
a A female of reproductive age with no medical 
contraindications to donation;
b 
b1 Repeatedly attested to her conclusion of parity;
b2 Signed an advanced directive for post-mortem 
organ donation;
c No history of uterine damage or disease, 
d Responsibility to consent, informed enough 
to make a responsible decision, and not under 
coercion. 
3. The health care team
a Part of an institution that meets Moore’s third 
criterion23, as it pertains to institutional stabil-
ity;, 
b Able to provide adequate informed consent to 
both parties regarding risks, potential sequel-
ae, and chances of success and failure, 
c No conflict of interest independently or with 
either party;
d The duty to preserve anonymity if the donor 
or recipient do not explicitly waive this right”. 
Uterus Transplant: 
Characteristics and Complications
Transplantology has made giant steps from 
the viewpoint of surgical techniques and control 
of organ rejection, and in this concern uterine 
transplantation has a unique peculiarity, aimed 
at preserving the functionality of the uterus in 
relation to the pregnancy and the birth of healthy 
babies. Uterine transplantation does not fall with-
in the category of scientific research, but rather 
therapeutic one, since women who undergo it aim 
to gain the ability to get pregnant, benefiting in 
this way of the possible positive outcome of such 
experimental procedure.
Several complications can arise after trans-
plantation, which are the same that may poten-
tially arise in any surgery such as postoperative 
bleeding, possible infections that may lead to 
severe illness up to death or to the removal of 
the transplanted organ24. Immunosuppressants, 
which have to be necessarily taken after trans-
plant make treatment of infections and tissue 
recovery more complex, due to the weakening of 
the immune system they cause. Moreover, gen-
eral medical complications may manifest them-
selves (pulmonary embolism, myocardial infarc-
tion, atrial fibrillation, pleural effusion, etc.). The 
point is that in case of uterus transplantation, 
immunosuppressive therapy has to be contin-
ued during the whole pregnancy and until birth, 
when the allograft uterus is removed. For that 
reason, the complications that this therapy may 
cause for fetal development Have to be evidenced 
and reported. Unfortunately, the only available 
information on the safety of new drugs during 
pregnancy and lactation at the moment is from 
experimental and preclinical animal studies and 
from human case reports25.
Uterine transplantation is peculiar due to the 
fact that the uterus is not a life-sustaining organ 
(such as heart, liver or kidney), but it is just an 
“instrumental organ” with the only function to 
give back to an unfertile woman the ability to 
become pregnant. In general terms, if an organ 
transplant should be considered ethically accept-
able when it is enables the patient to go on living 
(heart transplant is emblematic in this regard), 
those transplants that are not life-saving, but 
merely aimed at restoring lost organ functions, 
are much more controversial in ethical nature, 
especially when they entail significant risk or 
have a relatively low possibility of success17. An 
example is that of hand transplants. It is well 
documented that several patients who underwent 
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such surgery have later demanded to have the 
transplanted hand removed, not because of his-
tocompatibility, but due to psychological issues 
arising from the perception of the transplanted 
hand as something not belonging to one’s own 
body26.
Ethical and Medico-legal Issues
Major ethical issues related to uterine trans-
plant are: a) the validity of consent to explantation 
(particularly from a living donor) and implan-
tation, owing to the dangerous nature of such 
procedures, b) the use of organs from deceased 
rather than living donors, c) the collection and 
equal distribution of organs, which are of limited 
supply, but at the same time of high demand27.
Research has shown that transplants have bet-
ter chances of success if the organ comes from a 
donor related to the recipient, and in case of uterus 
possibly sisters or mothers. It is worth specifying 
that organ donations between kins are an altruistic 
act, thus justifiable as such. The fact that psycho-
logical dependency may develop between donor 
and recipient has not to be overlooked. Such an 
outcome, however, may arise in all cases of trans-
plants inter vivos. Uterine transplants have better 
chances of success if the organ comes from a liv-
ing donor. However, serious ethical issues come to 
the fore, namely an organ donation without a real 
therapeutic need. The uterus is a single, non-vital 
organ, nevertheless, the donor is affected in her 
physical integrity. Misgivings come from the in-
trinsic nature of such a procedure: it is not meant 
to be life-saving, as would be the case with kidney 
or liver transplants, but it only serves the purpose 
of achieving motherhood. When it comes to uter-
ine transplant and its high complexity, the woman 
health is in severe danger, and the likelihood of 
organ rejection and fetal death is high, which nul-
lifies the very purpose of the surgery itself28. One 
more reason for skepticism is the need to remove 
the organ from a deceased donor. The shortage of 
available organs is well known; hence, it is ques-
tionable that they should be used for non-thera-
peutic interventions. Currently, uterine transplants 
have extremely low chances of success; it is then 
hardly justifiable to massively invest in such pos-
sibility, blocking the limited financial resources 
towards procedures with higher success rates.
A great deal of misgivings arise in the phase 
following organ explanation, that is when the 
actual transplant takes place, being such a sur-
gical procedure still experimental. The recipient, 
as is the case in any other transplant, will have 
to undergo immunosuppressive drug therapy to 
prevent organ rejection which, in addition to 
exposing the patient to the risk of diseases (e.g., 
hypertension, diabetes, cataracts, osteoporosis), 
is highly harmful to the fetus. Therefore, the 
wish to have an offspring may be nullified by 
anti-rejection therapies, which are mandatory for 
any transplant and can greatly harm the possibly 
conceived fetus. To avoid immunosuppressive 
therapy for life, two follow-up procedures are 
necessary: cesarean section and hysterectomy. It 
is also worth noting that the uterus is not a “stat-
ic” organ such as a kidney or liver, which keep 
the same size once implanted in the recipient. 
During pregnancy, in fact, the uterus increases 
in size and width, and in case of thrombosis, it 
should be removed in order to save the mother’s 
life, thus terminating the pregnancy. In addition 
to all that, there are many technical difficulties, 
mostly associated with the intricate reattachment 
of veins and arteries9.
Uterine transplantation is hazardous from a 
psychological standpoint as well: possible organ 
rejection would only add to the sense of anguish 
and frustration already afflicting women due to 
their inability to have a pregnancy.
Such considerations are true for transplants 
from both deceased and live donors. Besides, in 
the latter cases, it should be kept in mind that 
uterine explanation is an extremely risky and a 
long surgical procedure.
Legal Regulation of Organ Transplants
Uterus transplant needs to be assessed from 
a legal perspective as well. Every country regu-
lates transplants in different ways, but the Italian 
framework is here detailed.
Italian law draws a distinction between trans-
plants from deceased donors and those inter 
vivos. Law n. 91, 1999 regulates the former, 
whereas transplants from live donors may be 
carried out in compliance with Ministerial de-
cree n.116, from 16th April 2010 (Regulation of 
transplantation activities from live donors)29. Art. 
5 of the Italian Civil Code sets forth the principle 
according to which “any actions on one’s own 
body when causing permanent damage to physi-
cal integrity or when violating law, public order 
or decency are prohibited”. Italian lawmakers 
have enacted several laws that constitute excep-
tions to the above-mentioned principle, namely 
law 458, from 1967, which deals with kidney 
transplants, law n. 483, from 1999, regulating 
partial liver explantation, law n. 219 from 2005, 
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which addresses transfusion-related activities and 
the national production of hemoderivatives, by 
repealing previous law n. 107 from 1990 on blood 
transfusions. Yet, medical and scientific advance-
ments have made possible some transplants that 
are not yet regulated, uterus transplantation being 
one of those. How should legal scholars approach 
the issue of still unregulated transplants, among 
which uterine transplant?
Uterus donation represents an act of “disposal 
of one’s body for the benefit of the recipient, which 
is aimed at gaining an advantage for a woman 
other than the donor. In order for such an act to be 
deemed legal, it must not compromise the woman 
donor’s physical and functional integrity. Based on 
such a principle, uterine transplants are lawful on-
ly when the donors are menopausal women, who 
have no longer the ability to procreate, and would 
therefore be unaffected in their physical integrity 
by the loss of their uterus. On the contrary, lays 
the choice of a woman in fertile age, but close 
to menopause, who has already born children. 
In such an instance, the donor could still have 
children in the future while donating her uterus 
for transplant would then deprive her of any fu-
ture prospect to have more children. In our view, 
uterus transplantation should be deemed lawful in 
such hypothetical case, irrespective of its being a 
non-vital organ. However, each instance ought to 
be weighed on a case-by-case basis, thoroughly 
assessing the motivations behind the prospective 
donor’s choice to have her womb removed, and the 
recipient’s decision to undergo such a hazardous 
procedure, with a highly uncertain outcome. 
Informed Consent
Law decree n. 116, from 16th April 2010, lays 
out a set of regulations targeted to the organ 
transplant-related activities from live donors30. 
Article 2 codifies the institution of expert com-
mittees due to handle all those issues stemming 
from living donor transplants. The committee is 
tasked with “verifying that both recipients and 
prospective donors have acted in compliance with 
informed consent principles, which consent must 
be free and thorough, and have received all pos-
sible information pertaining to their clinical case, 
the risk factors involved and the actual odds of 
success with transplants from deceased or living 
donors, in terms of survival rates for both organs 
and patients themselves”. 
The issue of obtaining informed consent in 
uterine transplant cases is particularly sensitive 
in nature. Women who place themselves on the 
waiting list for such surgery should be fully 
aware of the often lengthy wait that it requires. 
In Italy, organs must come from deceased donors, 
with immunological compatibility. When a wom-
an is put on the waiting list, it is quite difficult to 
predict how long it might take before the actual 
surgery can be performed. In fact, since the organ 
to be transplanted comes from a deceased donor 
and must be compatible with the prospective 
recipient, it is just impossible to schedule the 
surgery, which might be performed at any time. 
Such a degree of uncertainty entails significant 
emotional and psychological strain, which the 
recipient has to be made aware of. 
Medical staff should inform patients that any 
future successful pregnancy, granted that there 
even is one, will be carried to term with a ce-
sarean section. Therefore, the patient will have 
to undergo three different surgical operations: 
uterus transplant, cesarean section and uterus 
removal, not to mention artificial insemination, 
which is itself an invasive kind of procedure. 
Doctors should make it absolutely clear to their 
patients that such medical procedures may give 
rise to complications, and explain exactly what 
kinds of unwanted side-effects might come into 
being. Patients ought to be informed as to the 
immunosuppressive drugs until the transplanted 
womb can be removed. Such immunosuppres-
sants could damage some organs, kidneys for in-
stance, increase the likelihood to develop cancer 
and turn out to be harmful to the fetus as well.
Lastly, in order to avoid possible disappoint-
ment in patients, women should be made aware 
that the transplanted womb will not convey the 
feeling of contraction, neither will they perceive 
the fetus pressing against the inner walls; women 
will be able to make a thoroughly informed deci-
sion on whether to accept the surgical risks and 
the immunosuppressive drug therapy.
The acceptability of an ill-defined, unidenti-
fied risk constitutes an ethical issue, since uter-
us transplantation entails hazards for both the 
mother and the embryo which is implanted into 
her womb30.
Conclusions
Women diagnosed with uterine factor infertil-
ity can fulfill their wish to have a child through 
surrogacy, which is nonetheless illegal in many 
countries. Uterus transplantation, however, can 
be a sustainable alternative for women who wish 
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to achieve motherhood. Uterine transplant is still 
an experimental procedure; as a general princi-
ple, such transplants designed to make childbirth 
possible is ethically acceptable. Yet, there are 
correlated issues that must be weighed carefully 
before an uterine transplant can become a rou-
tine surgical practice. It is therefore paramount 
to carefully evaluate the risk-benefit ratios and 
reflect whether the longing for motherhood may 
warrant an acceptance of the hazards inherent in 
the procedure, for both the mother and the fetus. 
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